{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:26Z","timestamp":1791396086616,"version":"4.3.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fecal microbiota transplantation (FMT) is the cost-effective strategy for managing recurrent Clostridioides difficile infection (rCDI). Prior costing models assumed FMT administration via colonoscopy. With the commercialization of microbiota therapeutics for rCDI, this study sought to determine the impact of commercial, Food and Drug Administration (FDA) approved microbiota-based therapeutics relative to traditional FMT on the cost-effectiveness for rCDI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a Markov model to simulate a cohort of patients with rCDI to evaluate the cost-effectiveness of varied methods of FMT administration for rCDI. The model includes estimates of cure, recurrence, and mortality. Data sources were taken from national guidelines and published literature on treatment outcomes. Outcome measures were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FMT by colonoscopy is the cost-effective strategy for preventing second or subsequent rCDI with an incremental cost-effectiveness ratio (ICER) of $44 158. Assuming a willingness-to-pay threshold of $100 000 per quality adjusted life years (QALY) gained, FMT by colonoscopy was optimal in the majority (70%) of simulations. At a willingness-to-pay threshold of $100 000 per quality adjusted life year (QALY), commercial, FDA approved microbiota therapeutics were not cost effective under any circumstance when donor-derived FMT products are available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Traditional FMT administered by colonoscopy is the optimal cost-effective strategy for preventing second or subsequent episodes of rCDI. If FMT is not available, then microbiota therapeutics are not a cost-effective option for rCDI at current pricing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag263","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:49:17Z","timestamp":1776430157000},"page":"391-398","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of Commercial or Traditional Fecal Microbiota Transplantation for Recurrent\n                    <i>Clostridioides difficile<\/i>\n                    Infection"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2849-659X","authenticated-orcid":false,"given":"William","family":"Hirsch","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-7358","authenticated-orcid":false,"given":"Eva A","family":"Enns","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Management, School of Public Health, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-3188","authenticated-orcid":false,"given":"Alexander","family":"Khoruts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-0231","authenticated-orcid":false,"given":"Radha","family":"Rajasingham","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-3761","authenticated-orcid":false,"given":"Byron P","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026100713425297400_ciag263-B1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. Burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100713425297400_ciag263-B2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12879-016-1786-6","article-title":"Cost of hospital management of Clostridium difficile infection in United States: a meta-analysis and modelling study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026100713425297400_ciag263-B3","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026100713425297400_ciag263-B4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(05)70215-2","article-title":"Treatment of Clostridium difficile-associated disease: old therapies and new strategies","volume":"5","author":"Aslam","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2026100713425297400_ciag263-B5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J Infect"},{"key":"2026100713425297400_ciag263-B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100713425297400_ciag263-B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12064","article-title":"Consequences of Clostridium difficile infection: understanding the healthcare burden","volume":"18","author":"Bouza","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026100713425297400_ciag263-B8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1017\/ice.2016.246","article-title":"A comprehensive study of costs associated with recurrent Clostridium difficile infection","volume":"38","author":"Rodrigues","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026100713425297400_ciag263-B9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA clinical practice guideline on fecal Microbiota-based therapies for select gastrointestinal diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"key":"2026100713425297400_ciag263-B10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026100713425297400_ciag263-B11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026100713425297400_ciag263-B12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciz318","article-title":"Cost-effectiveness of treatment regimens for Clostridioides difficile infection: an evaluation of the 2018 Infectious Diseases Society of America guidelines","volume":"70","author":"Rajasingham","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026100713425297400_ciag263-B13","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/cid\/ciac207","article-title":"Cost-effectiveness of fecal Microbiota transplantation for first recurrent Clostridioides difficile infection","volume":"75","author":"Aby","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026100713425297400_ciag263-B14","doi-asserted-by":"crossref","first-page":"622949","DOI":"10.3389\/fcimb.2021.622949","article-title":"Stool banking for fecal Microbiota transplantation: methods and operations at a large stool bank","volume":"11","author":"Chen","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2026100713425297400_ciag263-B15","author":"U.S. Food and Drug Administration. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridioides difficile infection not responsive to standard therapies: guidance for industry","year":"2022"},{"key":"2026100713425297400_ciag263-B16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamainternmed.2016.9045","article-title":"Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection","volume":"177","author":"Stevens","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026100713425297400_ciag263-B17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189227","article-title":"National epidemiology of initial and recurrent Clostridium difficile infection in the veterans health administration from 2003 to 2014","volume":"12","author":"Reveles","year":"2017","journal-title":"PLoS One"},{"key":"2026100713425297400_ciag263-B18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/CMR.0000000000000871","article-title":"Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients","volume":"33","author":"Fortman","year":"2023","journal-title":"Melanoma Res"},{"key":"2026100713425297400_ciag263-B19","first-page":"1","article-title":"United States life tables, 2014","volume":"66","author":"Arias","year":"2017","journal-title":"Natl Vital Stat Rep"},{"key":"2026100713425297400_ciag263-B20","first-page":"1","volume-title":"Statistical brief (medical expenditure panel survey (US))","author":"Stagnitti","year":"2001"},{"key":"2026100713425297400_ciag263-B21","author":"IBM Corporation"},{"key":"2026100713425297400_ciag263-B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost task force report\u2013part I","volume":"13","author":"Hay","year":"2010","journal-title":"Value Health"},{"key":"2026100713425297400_ciag263-B23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1469-0691.2011.03571.x","article-title":"The economic burden of Clostridium difficile","volume":"18","author":"McGlone","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026100713425297400_ciag263-B24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/ice.2018.280","article-title":"Clostridium difficile infection increases acute and chronic morbidity and mortality","volume":"40","author":"Olsen","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026100713425297400_ciag263-B25","doi-asserted-by":"crossref","first-page":"ofy175","DOI":"10.1093\/ofid\/ofy175","article-title":"Predictors of mortality among a national cohort of veterans with recurrent Clostridium difficile infection","volume":"5","author":"Appaneal","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026100713425297400_ciag263-B26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/cid\/ciy715","article-title":"Outcomes of community and healthcare-onset Clostridium difficile infections","volume":"68","author":"Mora Pinzon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026100713425297400_ciag263-B27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/cid\/cir632","article-title":"Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection","volume":"53","author":"Gough","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026100713425297400_ciag263-B28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/M18-3635","article-title":"Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal Microbiota transplantation or antibiotics: a prospective cohort study","volume":"171","author":"Ianiro","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026100713425297400_ciag263-B29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ajg.2012.60","article-title":"Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection","volume":"107","author":"Brandt","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026100713425297400_ciag263-B30","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/jama.2017.17077","article-title":"Effect of oral capsule- vs colonoscopy-delivered fecal Microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial","volume":"318","author":"Kao","year":"2017","journal-title":"JAMA"},{"key":"2026100713425297400_ciag263-B31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.gastro.2011.11.037","article-title":"Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection","volume":"142","author":"Mattila","year":"2012","journal-title":"Gastroenterology"},{"key":"2026100713425297400_ciag263-B32","doi-asserted-by":"crossref","first-page":"2493901","DOI":"10.1080\/19490976.2025.2493901","article-title":"Fecal microbiota transplantation: a tale of two regulatory pathways","volume":"17","author":"Hoffmann","year":"2025","journal-title":"Gut Microbes"},{"key":"2026100713425297400_ciag263-B33","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s12325-023-02505-1","article-title":"Cost-effectiveness analysis of REBYOTATM (fecal Microbiota, live-jslm [FMBL]) versus standard of care for the prevention of recurrent Clostridioides difficile infection in the USA","volume":"40","author":"Lodise","year":"2023","journal-title":"Adv Ther"},{"key":"2026100713425297400_ciag263-B34","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s40121-025-01169-4","article-title":"Budget impact analysis of fecal Microbiota spores, live-brpk (formerly SER-109) for recurrent clostridioides difficile infection in the United States","volume":"14","author":"Wilson","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026100713425297400_ciag263-B35","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s12325-023-02506-0","article-title":"Budget impact analysis of REBYOTATM (fecal Microbiota, live-jslm [FMBL]) for preventing recurrent Clostridioides difficile infection in the US","volume":"40","author":"Lodise","year":"2023","journal-title":"Adv Ther"},{"key":"2026100713425297400_ciag263-B36","first-page":"CD013871","article-title":"Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100713425297400_ciag263-B37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10620-020-06185-7","article-title":"Fecal Microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis","volume":"66","author":"Ramai","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026100713425297400_ciag263-B38","doi-asserted-by":"crossref","first-page":"17562848211041004","DOI":"10.1177\/17562848211041004","article-title":"Systematic review with meta-analysis: encapsulated faecal microbiota transplantation - evidence for clinical efficacy","volume":"14","author":"Cold","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"2026100713425297400_ciag263-B39","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/2050640620957765","article-title":"Faecal microbiota transplantation for Clostridioides difficile infection: four years\u2019 experience of The Netherlands donor feces bank","volume":"8","author":"Terveer","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"2026100713425297400_ciag263-B40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2050640620967898","article-title":"A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group","volume":"9","author":"Keller","year":"2021","journal-title":"United Eur Gastroenterol J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag263\/68512939\/ciag263.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/391\/68512939\/ciag263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/391\/68512939\/ciag263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:43:02Z","timestamp":1791394982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/3\/391\/8706303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag263","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,6,11]]}}}